Akeso Biopharma

🌟 Join us at the 7th China International Import Expo, taking place from November 5-10 in Shanghai! We're excited to welcome you to Akeso booth, located at NB01. We look forward to seeing you there! #CIIE2024 #Akeso #NB01 #Shanghai

We are deeply honored to have been awarded both the Woman Leader and Research and Development Awards from BioCentury Inc. The BayHelix Group.

First Patient Enrollment in Phase 3 Trial of #Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors (#BTC), Compared to #Durvalumab. (HARMONi-GI-01/AK112-309 study). https://lnkd.in/gnXTWGuE

Phase 3 study in squamous cell carcinoma of the head and neck | The AK117-302 study represents a significant milestone as the first Phase 3 clinical trial investigating a CD47 monoclonal antibody therapy for solid tumors. It is also the fifth Phase 3 study for ivonescimab, utilizing PD-1/L1 monoclonal antibody therapy as a positive control, and the third Phase 3 study comparing ivonescimab with pembrolizumab. #ivonescimab #CD47 #ligufalimab #bispecific #immunotherapy Full release : https://lnkd.in/gT2ryyb6

Akeso released comprehensive data from its pivotal Phase 3 study (#AK111-301) evaluating #gumokimab (AK111), a humanized immunoglobulin (Ig) G1 monoclonal antibody (mAb) that selectively binds and neutralizes IL-17A, for the treatment of moderate to severe #plaquepsoriasis. This study was conducted in China and achieved its primary endpoint in 2023. https://lnkd.in/gZPFGbat

Breaking News📝 The latest results from the COMPASSION-16 phase 3 trial on #cadonilimab as a first-line treatment for persistent, recurrent, or metastatic cervical cancer have been published in @Nature Reviews Clinical Oncology Nature Portfolio. This highlights the significant clinical value and commercialization potential of cadonilimab in advancing standard treatments globally. https://lnkd.in/gjnHSvHC #cancertreatment #clinicaltrials #ctla4 #immunotherapy #cadonilimab #Akesobiopharma

We've seen significant progress in immune checkpoint inhibitors (ICIs)in cancer treatment, but challenges like varying patient responses and drug resistance remain. Akeso addresses these issues by developing bispecific antibodies and combining them with new targeted/mechanism therapies to overcome limitations. This strategy has allowed us to advance our gastric and lung cancer research to phase 3 trials. While drug development takes time, the urgency for effective treatments for patients is high. We are committed to improving R&D efficiency and protecting the value of innovation for patients.

When the triple synergistic effect of activating innate immunity, stimulating acquired immunity, and targeting angiogenesis is achieved, what hopes might emerge for tumor treatment? Motivated by encouraging preclinical research results, we are fully dedicated to this mission. Recently, we advanced a combination therapy of two internally developed innovative products (ivonescimab and the CD47 monoclonal antibody AK117) for first-line treatment of PD-L1 positive head and neck squamous cell carcinoma into Phase 3 clinical trial, successfully enrolling our first patient. The five-year survival rate for this disease is only about 3.6% in China, and we are determined to improve this challenging situation as quickly as possible. #AK112 #AK117 #CD47 #HNSCC #cancerimmunotherapy

Breaking News：Data from the COMPASSION-16 study have just been published in The Lancet 📖 This significant milestone highlights how cadonilimab is pushing the boundaries of medical research and making a real impact in cervical cancer treatment. #CervicalCancer #LANCET #cadonilimab https://lnkd.in/gJKdWmNc

Breaking News：The COMPASSION-16 study's positive PFS and OS data were published at #IGCS2024. #Cadonilimab with or without bevacizumab, demonstrated promising efficacy in treating persistent, recurrent, or metastatic #cervicalcancer, addressing a critical unmet need for patients without access to #bevacizumab. Additionally, cadonilimab offers significant benefits for all patients, regardless of PD-L1 expression status. #cadonilimab #cervicalcancer #cancerimmunotherapy #IGCS2024 #Akeso #COMPASSION16 Full press release: https://lnkd.in/gKsjb5_6